Emerging Agents in Renal Cell Carcinoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2015

AUTHORS

Sumanta Kumar Pal , David Y. Josephson , Przemyslaw Twardowski , David I. Quinn

ABSTRACT

The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of seven targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the seven agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, axitinib, and bevacizumab) and (2) inhibitors of the mammalian target of rapamycin (mTOR; everolimus and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies – ranging from vaccine therapy to cytotoxic chemotherapy – that may add to the current armamentarium for mRCC. More... »

PAGES

385-402

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_23

DOI

http://dx.doi.org/10.1007/978-3-319-17903-2_23

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030214848


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kidney Cancer Program, Division of Genitourinary Oncology, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Kidney Cancer Program, Division of Genitourinary Oncology, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pal", 
        "givenName": "Sumanta Kumar", 
        "id": "sg:person.01162002222.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.50956.3f", 
          "name": [
            "Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Josephson", 
        "givenName": "David Y.", 
        "id": "sg:person.0605012571.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605012571.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Twardowski", 
        "givenName": "Przemyslaw", 
        "id": "sg:person.01176726517.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176726517.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Developmental Therapeutics Program, Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Developmental Therapeutics Program, Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015", 
    "datePublishedReg": "2015-01-01", 
    "description": "The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of seven targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the seven agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, axitinib, and bevacizumab) and (2) inhibitors of the mammalian target of rapamycin (mTOR; everolimus and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies \u2013 ranging from vaccine therapy to cytotoxic chemotherapy \u2013 that may add to the current armamentarium for mRCC.", 
    "editor": [
      {
        "familyName": "Lara", 
        "givenName": "Primo N.", 
        "type": "Person"
      }, 
      {
        "familyName": "Jonasch", 
        "givenName": "Eric", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-17903-2_23", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-17902-5", 
        "978-3-319-17903-2"
      ], 
      "name": "Kidney Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "renal cell carcinoma", 
      "cell carcinoma", 
      "landscape of therapy", 
      "vascular endothelial growth factor", 
      "endothelial growth factor", 
      "antitumor immunity", 
      "cytotoxic chemotherapy", 
      "vaccine therapy", 
      "current armamentarium", 
      "mammalian target", 
      "therapy", 
      "growth factor", 
      "carcinoma", 
      "novel mechanism", 
      "agents", 
      "chemotherapy", 
      "armamentarium", 
      "disease", 
      "immunity", 
      "mechanistic categories", 
      "rapamycin", 
      "treatment", 
      "inhibitors", 
      "approval", 
      "past decade", 
      "current chapter", 
      "target", 
      "factors", 
      "mechanism", 
      "milestones", 
      "categories", 
      "decades", 
      "chapter", 
      "paradigm", 
      "community", 
      "mind", 
      "range", 
      "landscape", 
      "research community", 
      "axes", 
      "book"
    ], 
    "name": "Emerging Agents in Renal Cell Carcinoma", 
    "pagination": "385-402", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030214848"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-17903-2_23"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-17903-2_23", 
      "https://app.dimensions.ai/details/publication/pub.1030214848"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_171.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-17903-2_23"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_23'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_23'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_23'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-17903-2_23'


 

This table displays all metadata directly associated to this object as RDF triples.

135 TRIPLES      22 PREDICATES      66 URIs      59 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-17903-2_23 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N90a4d479887240d283de86e3c2d19a03
4 schema:datePublished 2015
5 schema:datePublishedReg 2015-01-01
6 schema:description The landscape of therapy for metastatic renal cell carcinoma (mRCC) has changed drastically over the past decade, hinging largely on the approval of seven targeted agents. While this undoubtedly represents a milestone in the treatment of this disease, it is critical to bear in mind that the seven agents fall broadly within two mechanistic categories: (1) vascular endothelial growth factor (VEGF)-directed therapies (sunitinib, sorafenib, pazopanib, axitinib, and bevacizumab) and (2) inhibitors of the mammalian target of rapamycin (mTOR; everolimus and temsirolimus). Other chapters in this book will delineate agents that are consistent with this paradigm. Ultimately, however, the research community will need to look toward agents that target distinct signaling axes or employ novel mechanisms to augment antitumor immunity. The current chapter explores a range of emerging therapies – ranging from vaccine therapy to cytotoxic chemotherapy – that may add to the current armamentarium for mRCC.
7 schema:editor N6e89c10bcec84e2f90276b4903f5f860
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Na20c2143ada24363bca8e790852e8539
11 schema:keywords agents
12 antitumor immunity
13 approval
14 armamentarium
15 axes
16 book
17 carcinoma
18 categories
19 cell carcinoma
20 chapter
21 chemotherapy
22 community
23 current armamentarium
24 current chapter
25 cytotoxic chemotherapy
26 decades
27 disease
28 endothelial growth factor
29 factors
30 growth factor
31 immunity
32 inhibitors
33 landscape
34 landscape of therapy
35 mammalian target
36 mechanism
37 mechanistic categories
38 metastatic renal cell carcinoma
39 milestones
40 mind
41 novel mechanism
42 paradigm
43 past decade
44 range
45 rapamycin
46 renal cell carcinoma
47 research community
48 target
49 therapy
50 treatment
51 vaccine therapy
52 vascular endothelial growth factor
53 schema:name Emerging Agents in Renal Cell Carcinoma
54 schema:pagination 385-402
55 schema:productId Nbe38a5c8b30146ec99c38c72f66af750
56 Nedd69f1e52a64ee4b759470b2a738503
57 schema:publisher Nefe4c8536d9c424fbe4d89550773c9d8
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030214848
59 https://doi.org/10.1007/978-3-319-17903-2_23
60 schema:sdDatePublished 2022-09-02T16:11
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N0d1013c2cdb44cf597e79af9493b3a32
63 schema:url https://doi.org/10.1007/978-3-319-17903-2_23
64 sgo:license sg:explorer/license/
65 sgo:sdDataset chapters
66 rdf:type schema:Chapter
67 N0d1013c2cdb44cf597e79af9493b3a32 schema:name Springer Nature - SN SciGraph project
68 rdf:type schema:Organization
69 N664e2de4d4f048cdbbbfddfdff0335db rdf:first sg:person.0605012571.62
70 rdf:rest N981b020f37b14a27998593c6938fecc6
71 N6e89c10bcec84e2f90276b4903f5f860 rdf:first Nde4eaa3503094bc9a8e3e999a381b71f
72 rdf:rest N8eb629311fdf437f8c0c9b372c721501
73 N8eb629311fdf437f8c0c9b372c721501 rdf:first N9b7b4fb609b244c59f916086015d3657
74 rdf:rest rdf:nil
75 N90a4d479887240d283de86e3c2d19a03 rdf:first sg:person.01162002222.57
76 rdf:rest N664e2de4d4f048cdbbbfddfdff0335db
77 N981b020f37b14a27998593c6938fecc6 rdf:first sg:person.01176726517.42
78 rdf:rest Nde77f7b3d7d1441294f1c0b9f980fb1f
79 N9b7b4fb609b244c59f916086015d3657 schema:familyName Jonasch
80 schema:givenName Eric
81 rdf:type schema:Person
82 Na20c2143ada24363bca8e790852e8539 schema:isbn 978-3-319-17902-5
83 978-3-319-17903-2
84 schema:name Kidney Cancer
85 rdf:type schema:Book
86 Nbe38a5c8b30146ec99c38c72f66af750 schema:name doi
87 schema:value 10.1007/978-3-319-17903-2_23
88 rdf:type schema:PropertyValue
89 Nde4eaa3503094bc9a8e3e999a381b71f schema:familyName Lara
90 schema:givenName Primo N.
91 rdf:type schema:Person
92 Nde77f7b3d7d1441294f1c0b9f980fb1f rdf:first sg:person.01013134010.15
93 rdf:rest rdf:nil
94 Nedd69f1e52a64ee4b759470b2a738503 schema:name dimensions_id
95 schema:value pub.1030214848
96 rdf:type schema:PropertyValue
97 Nefe4c8536d9c424fbe4d89550773c9d8 schema:name Springer Nature
98 rdf:type schema:Organisation
99 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
100 schema:name Biological Sciences
101 rdf:type schema:DefinedTerm
102 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
103 schema:name Biochemistry and Cell Biology
104 rdf:type schema:DefinedTerm
105 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
106 schema:familyName Quinn
107 schema:givenName David I.
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
109 rdf:type schema:Person
110 sg:person.01162002222.57 schema:affiliation grid-institutes:grid.410425.6
111 schema:familyName Pal
112 schema:givenName Sumanta Kumar
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162002222.57
114 rdf:type schema:Person
115 sg:person.01176726517.42 schema:affiliation grid-institutes:grid.410425.6
116 schema:familyName Twardowski
117 schema:givenName Przemyslaw
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176726517.42
119 rdf:type schema:Person
120 sg:person.0605012571.62 schema:affiliation grid-institutes:grid.50956.3f
121 schema:familyName Josephson
122 schema:givenName David Y.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605012571.62
124 rdf:type schema:Person
125 grid-institutes:grid.410425.6 schema:alternateName Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
126 Kidney Cancer Program, Division of Genitourinary Oncology, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
127 schema:name Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
128 Kidney Cancer Program, Division of Genitourinary Oncology, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA
129 rdf:type schema:Organization
130 grid-institutes:grid.42505.36 schema:alternateName Developmental Therapeutics Program, Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
131 schema:name Developmental Therapeutics Program, Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
132 rdf:type schema:Organization
133 grid-institutes:grid.50956.3f schema:alternateName Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA
134 schema:name Department of Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA
135 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...